| Date | Title | Description |
| 13.11.2024 | Andera Partners continues its international expansion and announces the opening of a Madrid office | Gonzalo Boada joins Andera Partners as a Director within the Andera MidCap team, which invests in medium-sized companies (with revenue between €50 and €500 million) to accelerate their change of scale and their internationalization. The mai... |
| 24.11.2021 | (English) Caixa Capital Risc leads sale of Sanifit Therapeutics to Vifor Pharma with upfront payment of €205M | Caixa Capital Risc, the venture capital subsidiary of CriteriaCaixa, today announces the sale of its portfolio company Sanifit Therapeutics to Vifor Pharma, a global pharmaceutical company that aims to become an industry leader in iron defi... |
| 22.11.2021 | Vifor Pharma adquirirá Sanifit para reforzar su cartera de productos en fase avanzada en nefrología |
St. Gallen, Suiza, y Palma, España, 19 de noviembre de 2021 – Vifor Pharma y Sanifit Therapeutics, compañía biofarmacéutica cardio-renal en fase clínica centrada en tratamientos para trastornos de calcificación vascular progresiva, han ... |
| 22.11.2021 | Vifor Pharma adquirirá Sanifit, participada por Ysios Capital, CaixaCR, AltaLS, ColumbusVP, Healthequity y el CDTI | 22/11/2021
Nota de prensa
VIFOR PHARMA ADQUIRIRÁ SANIFIT PARA REFORZAR SU CARTERA DE PRODUCTOS EN FASE AVANZADA EN NEFROLOGÍA.
• Vifor Pharma adquirirá Sanifit, una compañía biofarmacéutica cardio-renal en fase clínica centrada en tratam... |
| 22.11.2021 | Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology |
St. Gallen, Switzerland, and Palma, Spain, 19 November 2021 – Vifor Pharma and Sanifit Therapeutics, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today ann... |
| 11.02.2021 | Sanifit Granted Orphan Drug Designation by the FDA for SNF472 for the Treatment of Peripheral Arterial Disease in Patients with End-stage Kidney Disease | https://www.sanifit.com/sanifit-granted-orphan-drug-designation-by-the-fda-for-snf472-for-the-treatment-of-peripheral-arterial-disease-in-patients-with-end-stage-kidney-disease/ |
| 01.06.2020 | Sanifit Enhances Leadership Team with New Executive Appointments | Newly appointed VP of Business Development and SVP of Clinical Development each bring to Sanifit over 20 years of industry experience
Palma, Spain and San Diego, USA, 01 June 2020 – Sanifit, a clinical-stage biopharmaceutical company focus... |
| 30.10.2019 | Sanifit touts positive PhIIb data; REGENXBIO licenses Clearside Biomedical tech | → Rare disease biotech Sanifit — which in June, raised nearly $81 million in Spain’s largest-ever private biotech fundraise — has announced that its international Phase IIb CaLIPSO study of SNF472 met its primary endpoint. Th... |
| 30.10.2019 | Sanifit, owned by Ysios Capital, announces that the Phase 2b CaLIPSO trial of SNF472 met its primary endpoint | 30/10/2019
Nota de prensa
SANIFIT, OWNED BY YSIOS CAPITAL, ANNOUNCES THAT THE PHASE 2B CALIPSO TRIAL OF SNF472 MET ITS PRIMARY ENDPOINT.
• Venture capital firm Ysios Capital led the 36,6M€ Series C round in 2015 creating a relevant inter... |
| 28.06.2019 | Spain and San Diego Based Sanifit Raises $80.9 Million | Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced the completion of a €72.2 million (USD 80.9 million) total private fundraising.
The financing consis... |
| 28.06.2019 | Spain and San Diego Based Sanifit Raises $80.9 Million | Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced the completion of a €72.2 million (USD 80.9 million) total private fundraising.
The financing consis... |
| 28.06.2019 | Term Sheet — Friday June 28 | APPLE’S AUTONOMOUS VEHICLE AMBITIONS
Hello Term Sheet readers. Lucinda here again until Polina’s return following the July 4 holidays. In the meantime, please send deals to lucinda.shen@fortune.com.
Paid Content You can't secure what you ca... |
| 28.06.2019 | Alta Life Sciences participates in Sanifit’s 55,2M€ Series D round led by Caixa Capital Risc | Palma, Spain and San Diego, USA, 26 June 2019 – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced the completion of a €72.2 million (USD 80.9 million)... |
| 26.06.2019 | Sanifit announces €72.2M ($80.9M) financing in Spain’s largest private biotech fundraise | Palma, Spain and San Diego, USA – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced the completion of a €72.2 million (USD 80.9 million) total private... |
| 26.06.2019 | Caixa Capital Risc lidera la mayor ronda de biotecnología en España, con €55M en Sanifit. Participan Columbus, Alta Life y anteriores inversores. | 26/06/2019
Nota de prensa
CAIXA CAPITAL RISC LIDERA LA MAYOR RONDA DE BIOTECNOLOGÍA EN ESPAÑA, CON €55M. EN SANIFIT. PARTICIPAN COLUMBUS, ALTA LIFE Y ANTERIORES INVERSORES.
La entidad de capital riesgo (venture capital) Caixa Capital Ris... |
| 26.06.2019 | Sanifit Raises €72.2M in Financing | Sanifit, a Palma, Spain and San Diego, USA-based clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, closed a €72.2m ($80.9m) funding round.
The financing consists of:
– a €55.2m ... |
| 25.10.2016 | Spanish biotech sector gets a boost with $140 million VC fund | “With our recent investments we have been able to attract specialized international funds and corporate venture funds to Spain, which represents an inflection point for the country´s biotech sector,” said Joel Jean-Mairet, partner at Ysios ... |
| 07.06.2016 | Sanifit, participada por Ysios, incorpora a Preston S. Klassen como director médico y abre sede en EEUU | 07/06/2016
SANIFIT, PARTICIPADA POR YSIOS CAPITAL, INCORPORA A PRESTON S. KLASSEN COMO NUEVO DIRECTOR MÉDICO Y ABRE SEDE EN EEUU.
Sanifit, compañía participada por la entidad de capital riesgo (venture capital) Ysios Capital, ha incorpora... |
| 08.09.2015 | Laboratoris Sanifit Raises €36.6M in Series C Financing | Laboratoris Sanifit S.L., a Palma de Mallorca, Spain-based clinical-stage biopharmaceutical company, raised €36.6M (approx. $41M) in Series C financing.
The round was led by Ysios Capital with participation from new investors Lundbeckfond V... |
| 08.09.2015 | Sanifit cierra una ronda de €36,6M liderada por Ysios. Acuden Caixa CR, Lundbeck fonden, Forbion, Gilde, Edmond Rothschild y Baxter | 08/09/2015
SANIFIT CIERRA UNA RONDA DE €36,6 MILLONES LIDERADA POR YSIOS. ACUDEN CAIXA CAPITAL RISC, Y LOS INTERNACIONALES LUNDBECK FONDEN, FORBION, GILDE, EDMON DE ROTHSCHILD Y BAXTER.
La empresa biofarmacéutica Laboratoris Sanifit S.L.,... |
| 08.09.2015 | Sanifit raises €36.6M ($41.3M) in Series C financing round | Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company, today announces that it has raised €36.6M ($41.3M) in a Series C financing round. The company is focused on the development of SNF472, an experimental drug for the treatm... |
| 17.11.2014 | Caixa Capital Risc lidera una ronda de €3,6 millones en Sanifit | 17/11/2014
CAIXA CAPITAL RISC LIDERA UNA RONDA DE €3,6 MILLONES EN SANIFIT.
La entidad de capital riesgo (venture capital) Caixa Capital Risc, ha liderado una ronda de financiación de €3,6 millones en la empresa Laboratorios Sanifit, ubic... |
| - | Spanish biotech sector gets a boost with $140 million VC fund | Ysios Capital Directors Josep Ll. Sanfeliu (top left), Joël Jean-Mairet, Karen Wagner, Julia Salaverria (left to right), and Cristina Garmendia (right bottom).
Institutional and private investors have given the Spanish biotech sector a powe... |
